繁體中文
返回
- English
- 繁體中文
- 简体中文
- 深色
- 淺色
立即開戶
60 Degrees Pharmaceuticals | 10-K: FY2023 Annual Report
60 Degrees Pharmaceuticals | 10-K: FY2023 Annual Report
60 Degrees Pharmaceuticals | 10-K:2023財年年報
牛牛AI助理已提取核心訊息
60 Degrees Pharmaceuticals, a pharmaceutical company, has reported its annual financial performance and business developments. The company has decided not to recognize the benefits of U.S. Federal, state, and net deferred tax assets, leading to a full valuation allowance against its net deferred tax assets as of December 31, 2023, and December 31, 2022. The company did not establish reserves for uncertain tax positions as of the end of 2023 and 2022. Significant customers accounted for 92% of receivables and 93% of total net revenues as of December 31, 2023. The company's largest customer, the US government, ended its purchase support contract and clinical study in 2022, and no significant receivables or revenues from the government are anticipated in the near term. The company has exclusive relationships with distributors in...Show More
60 Degrees Pharmaceuticals, a pharmaceutical company, has reported its annual financial performance and business developments. The company has decided not to recognize the benefits of U.S. Federal, state, and net deferred tax assets, leading to a full valuation allowance against its net deferred tax assets as of December 31, 2023, and December 31, 2022. The company did not establish reserves for uncertain tax positions as of the end of 2023 and 2022. Significant customers accounted for 92% of receivables and 93% of total net revenues as of December 31, 2023. The company's largest customer, the US government, ended its purchase support contract and clinical study in 2022, and no significant receivables or revenues from the government are anticipated in the near term. The company has exclusive relationships with distributors in Australia and Europe, and any failure to perform by these distributors could disrupt patient access in those markets. The company's financial instruments are primarily cash, accounts receivable, inventory purchases, and borrowings, with a concentration of credit risk. Revenue is recognized in accordance with FASB ASC Topic No. 606, and the majority of revenues come from sales of its Arakoda™ product to resellers in the US and abroad. Research and development costs were recorded at $691,770 for the year ended December 31, 2023. The company's financial instruments are measured at fair value, with derivative liabilities carried at fair value based on Level 3 inputs. The company's future plans include managing its business in one identifiable segment and continuing to evaluate the impact of recently adopted and issued accounting pronouncements on its financial statement disclosures.
60 Degrees Pharmaceuticals,一家制藥公司公佈了其年度財務業績和業務發展。該公司決定不承認美國聯邦、州和淨遞延稅資產的利益,導致其2023年12月31日和2022年12月31日的淨遞延稅資產出現完全計價準備。該公司沒有爲2023年年末和2022年年末的不確定稅項設立準備金。顯著的客戶佔到了2023年12月31日應收賬款的92%和總淨收入的93%。該公司最大的客戶美國政府在2022年結束了其採購支持合同和臨床研究,未來沒有來自政府的重大應收賬款或收入。該公司在澳洲和歐洲擁有獨家經銷商關係,這些經銷商的表現如果出現問題可能會影響這些市場上患者的使用。該公司的財務工具主要是現...展開全部
60 Degrees Pharmaceuticals,一家制藥公司公佈了其年度財務業績和業務發展。該公司決定不承認美國聯邦、州和淨遞延稅資產的利益,導致其2023年12月31日和2022年12月31日的淨遞延稅資產出現完全計價準備。該公司沒有爲2023年年末和2022年年末的不確定稅項設立準備金。顯著的客戶佔到了2023年12月31日應收賬款的92%和總淨收入的93%。該公司最大的客戶美國政府在2022年結束了其採購支持合同和臨床研究,未來沒有來自政府的重大應收賬款或收入。該公司在澳洲和歐洲擁有獨家經銷商關係,這些經銷商的表現如果出現問題可能會影響這些市場上患者的使用。該公司的財務工具主要是現金、應收賬款、存貨採購和借款,信貸風險集中。按照FASB ASC 606準則確認營業收入,主要的收入來自於其Arakoda™產品在美國和國外的轉售商銷售。研發費用在2023年12月31日止年度記錄爲691,770美元。該公司的財務工具計量公允價值,衍生負債根據3級輸入的公允價值進行計提。該公司未來的計劃包括在一個可識別的業務領域中管理業務,並繼續評估最近採用和發佈的會計準則對其財務報表披露的影響。
有用
沒用
譯文內容由第三人軟體翻譯。
牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生,只对除中国内地以外的地区提供。
以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
風險及免責聲明
牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生,只对除中国内地以外的地区提供。
以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
我知道了
風險及免責聲明
牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生,只对除中国内地以外的地区提供。
以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
我知道了
資訊熱榜
更新時間